NeoPharm named Guillermo A. Herrera as president and CEO. Herrera spent 24 years at Abbott Laboratories and most recently served as senior vice president, international operations and president of Abbott International.
N. Anthony Coles, M.D., M.P.H., has been appointed as president and COO of NPS Pharmaceuticals. He had been senior vice president, commercial operations for Vertex.
Talecris Biotherapeutics has made three top appointments: Alberto Martinez, M.D., has assumed the position of president and CEO; John Hanson has assumed the position of CFO, and Mel Asbury has been named senior vice president of human resources.
Encysive Pharmaceuticals has named Gordon H. Busenbark CFO. Busenbark joins Encysive from Baxter Healthcare.
Adolor has hired Thomas Hess, CPA, as vice president, finance and CFO. Hess had been corporate controller at Vicuron Pharmaceuticals.
Metabolex hired Paul Quinlan as general counsel. He joins Metabolex from Maxygen, where he served as chief corporate securities counsel.
Neurocrine Biosciences has appointed Chris O'Brien, M.D., senior vice president of clinical development. Dr. O'Brien most recently held positions at Elan Pharmaceuticals and Prestwick Pharmaceuticals.
Clinical Data appointed two new key members of the company's senior management team: Carol Reed, M.D., as senior vice president and chief medical officer; and John A. Schultz as senior vice president, corporate development.
Timothy Moses has resigned as an officer and director of Nova Biogenetics.
Athenagen announced that co-founder (Ken) M. Kengatharan, Ph.D., joined the company in a full-time capacity as vice president, pre-clinical R&D.
GlaxoSmithKline made three senior appointments to lead its UK-based clinical-imaging and experimental-medicine research programs: Paul Matthews has been appointed vice president, imaging; Ed Bullmore has been appointed vice president, experimental medicine; Marc Laruelle has been appointed vice president for clinical molecular imaging.
Bentley Pharmaceuticals hired Fred Feldman, Ph.D., as vice president of research and development.
Ramkumar Mandalam, Ph.D., has joined Cellerant Therapeutics as vice president of pharmaceutical operations. Dr. Mandalam was formerly executive director of product development for Geron.
Lawrence R. Moreau has been elected to the board of directors of Sequenom.
HistoRx named Dr. Ronald M. Lindsay, Ph.D., former chief scientific officer and vice president of research and development at diaDexus, to its board of directors.
Admiral William J. Crowe has retired from the board of directors of Emergent Biosolutions.
Adams Respiratory Therapeutics named John N. Lilly to its board of directors.
SGX Pharmaceuticals has elected Karin Eastham to the company's board of directors.